KLBF – Booked a 9.36% net profit growth in 1H25

KLBF – Booked a 9.36% net profit growth in 1H25 Kalbe Farma (KLBF) records a IDR1.97 tn net profit in 1H25, rising 9.36% yoy from IDR1.8 tn. The increase was driven by higher sales, improved gross margin, and disciplined cost management, alongside non-operational gains. Net sales also reached IDR17.08 tn, up 4.59% yoy from IDR16.32 tn, supported by a strong performance in prescription drugs, health products, and distribution/logistics. Gross margins also improved to 41.1% yoy, driven by a favorable product mix and stable raw material prices. President Director Irawati Setiady noted that Kalbe’s strategy includes expanding its oncology ecosystem, developing biological drugs and medical devices, and rejuvenating consumer product brands. Despite global financial and geopolitical uncertainty, Kalbe maintained stable supply chains and inventory. The company continues to pursue efficiency via digitalization and targeted marketing, while also managing FX exposure on imported raw materials. KLBF maintains its 2025 sales and net profit growth outlook at 8%–10% yoy, and upholds a 45%–55% dividend payout ratio. It has also budgeted IDR250 bn for continued share buybacks, following IDR1 tn already executed. (Source : Bisnis Indonesia)